Update on Key Emerging Challenges in Cystic Fibrosis

Jennings, Mark T.; Riekert, Kristin A.; Boyle, Michael

doi:10.1159/000357646

Cited by 2,681 publications

(24 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this meta-analysis, we found that the prevalence of MRSA infection has climbed up over years. This increase is in line with previous reviews done by LiPuma, Kahl and Jennings et al [3,10,43]. They reported that MRSA infection among CF population has demonstrated a notable increase in prevalence over the last decades.…”

Section: Resultssupporting

confidence: 91%

Prevalence of Methicillin-Resistant Staphylococcus Aureus (MRSA) infection in patients with Cystic Fibrosis: a meta-analysis

Mohamed

Ali

Ibrahim

et al. 2019

Preprint

View full text Add to dashboard Cite

Background Methicillin-resistant staphylococcus aureus (MRSA) infection is increasingly being reported among patients with cystic fibrosis (CF) and contributes to pulmonary morbidity in CF, with poorer prognosis. The aim of this study was to assess the prevalence of MRSA infection in patients with CF. Methods We conducted this study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases of MEDLINE/PubMed, WHO-Virtual Health Library (VHL), ScienceDirect, Google Scholar and OpenGrey were searched to recruit the relevant articles. Pooled prevalence with the corresponding 95% confidence interval (CI) was calculated using OpenMeta Analyst software, and heterogeneity among studies was estimated using the I2 statistics. Results According to our inclusion criteria, 27 studies included a total of 47,413 patients were analyzed. The pooled prevalence of MRSA in patients with CF was 15.2% (95% CI 9.70%– 20.7%). Subgroup analyses and meta-regression showed that the prevalence of MRSA in patients with CF was significantly associated with different geographical areas (P<0.001), data collection method (P<0.001), sample obtaining source (P<0.001), and study year (P = 0.006). Conclusions prevalence of MRSA infection is increasing in patients with CF. the results of this study could provide a reference for further controlling transmission and the management of patients with CF. Healthcare providers need to be aware of the clinically important association between MRSA infection and CF to ensure effective management.

show abstract

Section: Resultssupporting

confidence: 91%

Prevalence of Methicillin-Resistant Staphylococcus Aureus (MRSA) infection in patients with Cystic Fibrosis: a meta-analysis

Mohamed

Ali

Ibrahim

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…CF is the most lethal inherited disease in the Caucasian population characterized by chronic airway inflammation (Jennings et al, 2014). The disease is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (Kerem et al, 1989), which encodes for a protein that, among different functions, includes the cAMPdependent chloride channel.…”

Section: Introductionmentioning

confidence: 99%

Chitosan as a non-viral co-transfection system in a cystic fibrosis cell line

Fernández

Santos-Carballal

Weber

et al. 2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Successful gene therapy requires the development of suitable vehicles for the selective and efficient delivery of genes to specific target cells at the expense of minimal toxicity. In this work, we investigated a non-viral gene delivery system based on chitosan (CS) to specifically address cystic fibrosis (CF). Thus, electrostatic self-assembled CS-pEGFP and CS-pEGFPsiRNA complexes were prepared from high-pure fully characterized CS (Mw ~20 kDa and degree of acetylation ~30%). The average diameter of positively-charged complexes (i.e.  ~ +25 mV) was ~200 nm. The complexes were found relatively stable over 14 h in OptiMEM. Cell viability study did not show any significant cytotoxic effect of the CS-based complexes in a human bronchial cystic fibrosis cell line (s). We evaluated the transfection efficiency of this cell line with both CS-pEGFP and co-transfected with CS-pEGFP-siRNA complexes at (N/P) charge ratio of 12. We reported an increase in the fluorescence intensity of CS-pEGFP and a reduction in the cells co-transfected with CS-pEGFP-siRNA. This study shows proof-of-principle that co-transfection with chitosan might be an effective delivery system in a human CF cell line. It also offers a potential alternative to further develop therapeutic strategies for inherited disease treatments, such as CF.

show abstract

“…7,8 Complicated and time-consuming treatment regimens, which may result in low adherence to medications, are a challenge in the management of patients with CF. 9 Low adherence to pulmonary medications in patients with CF is associated with more frequent pulmonary exacerbations 10 and more CF-related hospitalizations and higher health-care costs, 11 all of which may result in reduced health care-related quality of life. 12 In addition to pulmonary medications, more than 80% of patients with CF younger than 40 years are prescribed pancreatic enzyme replacement therapy (PERT) to treat EPI.…”

Section: Introductionmentioning

confidence: 99%

Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy

Trapnell

Khurmi

et al. 2020

Chron Respir Dis

View full text Add to dashboard Cite

We investigated the relationship between self-reported adherence to pancreatic enzyme replacement therapy (PERT), nutritional status, and all-cause hospitalization in cystic fibrosis (CF) patients with a record of PERT use. Association of self-reported annual PERT use rate (adherence) with annual hospital admission rate (HAR) and annual total hospital nights (THNs) were analyzed for 5301 children (2000–2012) and 13,989 adults (2000–2013) from the CF Foundation Patient Registry. Multivariate linear regression was used to determine the association of HAR and THN with mean annual PERT use rate, cumulative PERT use rate, mean body mass index (BMI) (adult) or BMI percentile (pediatric), age, and sex. The median annual PERT use rate was 87% in children and 80% in adults. Statistically, higher annual PERT use, longer cumulative PERT, and higher BMI percentile (children) or BMI (adults) were significantly ( p < 0.0001) associated with lower annual HAR and fewer annual THN in children and adults. Female sex was associated with higher annual HAR and more annual THN in children and adults ( p < 0.05). Results indicate self-reported adherence to PERT, increased BMI, and male sex were associated with fewer hospital admissions and annual hospital nights in CF patients.

show abstract

Update on Key Emerging Challenges in Cystic Fibrosis

Cited by 2,681 publications

References 89 publications

Prevalence of Methicillin-Resistant Staphylococcus Aureus (MRSA) infection in patients with Cystic Fibrosis: a meta-analysis

Prevalence of Methicillin-Resistant Staphylococcus Aureus (MRSA) infection in patients with Cystic Fibrosis: a meta-analysis

Chitosan as a non-viral co-transfection system in a cystic fibrosis cell line

Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy

Contact Info

Product

Resources

About